Searched for
GAVIS PHARMA
Lupin Q3 results: Loss widens to Rs 835 crore on higher taxTax expenses for the quarter jumped to Rs 767 crore from Rs 245.40 crore.- Lupin CFO quits, to pursue opportunities outside pharmaSwaminathan as the CFO of Lupin, was part of some of company's biggest mergers and acquisition in US and Japan
- US opioid crisis hits Indian pharma companiesThe total market size of opioid-based painkillers is estimated at $24 billion, with Fentanyl and Oxycontin being some of the commonly presc...
- Lupin makes impairment provision for GavisLupin took a hit worth Rs 1,464.35 crore on US-based Gavis, which it acquired in 2015 for $880 million (Rs 5,610 crore then).
- IIFL’s Bhavesh Gandhi prefers mid-cap to frontline pharma: Here’s why"For Lupin, migrating the portfolio from a regular oral solids to specialties would take time."
- Lupin reports Rs 777 crore Q4 loss on one-time impairment provisionsThe company had reported Rs 707 crore profit for the year-ago quarter.
- Lupin net skids, says Gavis deal ‘shy’ of expectationsThe business fell 13.2% to Rs 1,900.7 crore from a year earlier and contributed 46% of sales.
- GAVIS Pharma LLC looking to exit Bengaluru-based Wintac LtdGavis Pharma LLC is now exploring options to exit its listed Indian arm. Wintac Ltd was not part of the 2015 deal struck between Lupin & Ga...
- Indian pharma takes M&A route to build a global footprintLast week Dr. Reddy's acquired a portfolio of eight complex generics in the US from Teva in a deal worth $350 million.
- Lupin launches generic insomnia drug in USDrug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.
- Lupin completes acquisition of GAVIS PharmaThe acquisition enhances the company's scale in the US generic market and also broadens its pipeline in dermatology and controlled substanc...
- Lupin, Gavis to sell 2 drugs to fulfil US FTC conditionThe acquisition creates the fifth largest portfolio of abbreviated new drug application (ANDA) filings with the USFDA, addressing a USD 63....
- It may take another quarter for Lupin to post a robust showMumbaibased pharma company Lupin has posted better-than-expected numbers after reporting dismal figures for four successive quarters.
- InvaGen, Exelan acquisition will give Cipla manufacturing plant, R&D base in USCipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...
- Buyouts unlikely to harm debt-free Lupin's healthWith no new blockbuster drugs going off patent in the near term, generic pharma companies have to explore new areas of growth like specialt...
- Lupin buys US generics firm Gavis for Rs 5606 croreThe deal, which is cash-free and debt-free, widens the company's pipeline in dermatology and controlled substance products, Lupin said.
- Lupin acquires US-based Gavis Pharma for 5,600 crore; Q1 PAT down 16%, stock slumpsShares of pharmaceuticals major Lupin plunged about 6% in intraday on Thursday as the company disappointed with its Q1 results.
- Controversial vaccine studies: Why is Bill & Melinda Gates Foundation under fire from critics in India?Bill & Melinda Gates Foundation has funded two entities that have played a key role in the immunization programme and are both under fire f...
- Bill & Melinda Gates Foundation: GAVI & PHFI help create incentives for pharma cos to make low-cost vaccinesThe project used vaccines that are licensed in India and that have been administered safely around the world tens of millions of times, pre...
- Foreign Investment Promotion Board clears 14 FDI proposals worth Rs 1,528 croreThe proposals of Agilent Technologies, Christine ComarmondMargotin, HLG Enterprises, Gstaad Hotels and three others have been rejected.
Load More
